Higher Incidence of Acute Kidney Injury With Intravenous Colistimethate Sodium Compared With Polymyxin B in Critically Ill Patients at a Tertiary Care Medical Center

Falagas, 2006, Toxicity of polymyxins: a systematic review of the evidence from old and recent studies, Crit Care, 10, R27.F, 10.1186/cc3995

Li, 2006, Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections, Lancet Infect Dis, 6, 589, 10.1016/S1473-3099(06)70580-1

Linden, 2006, Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia, Clin Infect Dis, 43, S89, 10.1086/504485

Kwa, 2007, Polymyxin B: similarities to and differences from colistin (polymyxin E), Expert Rev Anti Infect Ther, 5, 811, 10.1586/14787210.5.5.811

Nord, 1964, Polymyxin B and colistin. A critical comparison, N Engl J Med, 270, 1030, 10.1056/NEJM196405142702002

Levin, 1999, Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, Clin Infect Dis, 28, 1008, 10.1086/514732

Falagas, 2010, Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients, Int J Antimicrob Agents, 35, 194, 10.1016/j.ijantimicag.2009.10.005

Kellum, 2008, Definition and classification of acute kidney injury, Nephron Clin Pract, 109, c182, 10.1159/000142926

Doshi, 2011, Nephrotoxicity associated with intravenous colistin in critically ill patients, Pharmacotherapy, 31, 1257, 10.1592/phco.31.12.1257

Hartzell, 2009, Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center, Clin Infect Dis, 48, 1724, 10.1086/599225

Pogue, 2011, Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system, Clin Infect Dis, 53, 879, 10.1093/cid/cir611

Deryke, 2010, Colistin dosing and nephrotoxicity in a large community teaching hospital, Antimicrob Agents Chemother, 54, 4503, 10.1128/AAC.01707-09

Bellomo, 2004, Acute Dialysis Quality Initiative workgroup: acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group, Crit Care, 8, R204, 10.1186/cc2872

Ouderkirk, 2003, Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria, Antimicrob Agents Chemother, 47, 2659, 10.1128/AAC.47.8.2659-2662.2003

Mendes, 2009, Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use, Ann Pharmacother, 43, 1948, 10.1345/aph.1M277

Oliveira, 2009, Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity, Diagn Microbiol Infect Dis, 65, 431, 10.1016/j.diagmicrobio.2009.07.018

Esaian, 2012, Effectiveness and tolerability of a polymyxin B dosing protocol, Ann Pharmacother, 46, 455, 10.1345/aph.1Q294

Kubin, 2012, Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy, J Infect, 65, 80, 10.1016/j.jinf.2012.01.015

Teng, 2008, Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria, Int J Antimicrob Agents, 31, 80, 10.1016/j.ijantimicag.2007.08.004